Commonwealth Coat of Arms of Australia

 

PB 38 of 2024

National Health (April 2024 Flow on price reductions for brands of combination items) (Exercise of Ministerial discretion) Determination 2024

National Health Act 1953

I, Nikolai Tsyganov, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care make this determination under subsection 99ADHB(6) of the National Health Act 1953.

Dated      27   March 2024

 

 

 

 

 

 

 

 

 

NIKOLAI TSYGANOV

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health and Aged Care

 

 

 

 

 

 

 

1  Name of Determination

 (1) This instrument is the National Health (April 2024 Flow on price reductions for brands of combination items) (Exercise of Ministerial discretion) Determination 2024. 

 (2) This instrument may also be cited as PB 38 of 2024.

2  Commencement

  This instrument commences the day after registration.

3  Definition

 Note: A number of expressions used in this instrument are defined in Part VII the Act,

 

In this instrument:

 

 Act means the National Health Act 1953.

4  Authority

This instrument is made under subsection 99ADHB(6) of the Act.

5  Brand of pharmaceutical item with approved ex-manufacturer price not reduced

I determine under subsection 99ADHB(6) of the Act that, for the purposes of subsection 99ADHB(2), the approved ex-manufacturer price, and each of the claimed prices (if applicable) of each brand of pharmaceutical item specified in column 2 in the table in Schedule 1 is not reduced on 1 April 2024.

Schedule 1— Brand of pharmaceutical item with approved ex-manufacturer price not reduced

 

Column 1

Column 2

Item

Brand of Pharmaceutical Item

 

Drug

Form

Manner of administration

Brand

1

Fosnetupitant with palonosetron

Solution concentrate for I.V. infusion containing fosnetupitant 235 mg (as chloride hydrochloride) and palonosetron 250 microgram (as hydrochloride)

Injection

Akynzeo IV

2

Olmesartan with amlodipine and hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg

Oral

APO-Olmesartan/Amlodipine/HCTZ 40/10/12.5

 

3

Olmesartan with amlodipine and hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg

Oral

Olmekar HCT 40/10/12.5

 

4

Olmesartan with amlodipine and hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg

Oral

Olamlo HCT 40/10/12.5

 

5

Olmesartan with amlodipine and hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg

Oral

 

Sevikar HCT 40/10/12.5

 

6

Olmesartan with amlodipine and hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg

Oral

APO-Olmesartan/Amlodipine/HCTZ 40/10/25

 

7

Olmesartan with amlodipine and hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg

Oral

Olamlo HCT 40/10/25

8

Olmesartan with amlodipine and hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg

Oral

Olmekar HCT 40/10/25

9

Olmesartan with amlodipine and hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg

Oral

Sevikar HCT 40/10/25

10

Olmesartan with amlodipine and hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg

Oral

APO-Olmesartan/Amlodipine/HCTZ 40/5/12.5 tablet

11

Olmesartan with amlodipine and hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg

Oral

Olamlo HCT 40/5/12.5

12

Olmesartan with amlodipine and hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg

Oral

Olmekar HCT 40/5/12.5

13

Olmesartan with amlodipine and hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg

Oral

Sevikar HCT 40/5/12.5

14

Olmesartan with amlodipine and hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg

Oral

APO-Olmesartan/Amlodipine/HCTZ 40/5/25 tablet

15

Olmesartan with amlodipine and hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg

Oral

Olamlo HCT 40/5/25

16

Olmesartan with amlodipine and hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg

Oral

Olmekar HCT 40/5/25

17

Olmesartan with amlodipine and hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg

Oral

Sevikar HCT 40/5/25

18

Sitagliptin with metformin

Tablet (modified release) containing 100 mg sitagliptin with 1000 mg metformin hydrochloride

Oral

Janumet XR

19

Sitagliptin with metformin

Tablet (modified release) containing 100 mg sitagliptin with 1000 mg metformin hydrochloride

Oral

Sitagliptin/Metformin Sandoz XR

20

Sitagliptin with metformin

Tablet (modified release) containing 50 mg sitagliptin with 1000 mg metformin hydrochloride

Oral

Janumet XR

21

Sitagliptin with metformin

Tablet (modified release) containing 50 mg sitagliptin with 1000 mg metformin hydrochloride

Oral

Sitagliptin/Metformin Sandoz XR